print logo

Contact Our Offices

Clinical Trials

Reset Text Size: A A A

Wet Age Related Macular Degeneration

Active Studies

CEDAR (Allergan)

A 2 year, phase 3 study on the safety and efficacy of Abicipar Pegol (AGN-150998) in patients with neovascular age-related macular degeneration.

HAWK (Alcon)

A phase 3, two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration.

LADDER (Genentech)

A 20 month, phase 2, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

ONYX (Regeneron)

A 9 month, randomized, double-masked, active-controlled phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration.

SF0166-C-002(SciFluor Life Sciences)

A Phase I/II,2 month, randomized, double-masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of SF0166, topical ophthalmic solution in the treatment of neovascular age-related macular degeneration.

Completed Studies

ANCHOR (Genentech)

Phase 3 double masked active treatment of the efficacy and safety of ranibizumab (Lucentis) compared to Visudyne for the treatment of Wet AMD.

CABERNET (Neovista)

Phase 3 study for the use of radiation with the Epi-Rad 90 system to treat Wet AMD.

CAPELLA (Regeneron)

A 1 year, phase2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration.

ECLIPSE (Ophthotech)

A 2 year Phase 3 study to determine the safety and efficacy of E10030 (Fovista) in combination with ranibizumab (Lucentis) compared to ranibizumab (Lucentis) monotherapy in Wet AMD.

EMERGE (Iconic Therapeutics)

A 6 month, phase 2, randomized, double-masked, multicenter, active-controlled study evaluating administration of repeated intravitreal doses of hI-con1 in patients with choroidal neovascularization secondary to age-related macular degeneration.

HARBOR (Genentech)

Phase 3 randomized treatment study of the efficacy and safety of different doses of ranibizumab (Lucentis) administered monthly or as needed.

HORIZON (Genentech)

Follow up study to evaluate the safety and tolerability of ranibizumab (Lucentis).

MARINA (Genentech)

Phase 3 double masked active treatment controlled study of the efficacy and safety of ranibizumab (Lucentis).

NEXUS (Lpath)

A 9 month Phase 2A study that is evaluating ISONEP as either monotherapy or adjunctive therapy to ranibizumab (Lucentis), bevacizumab (Avastin) or aflibercept (Eylea).

OPH1004 (Ophthotech)

A 2 year, phase2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of FOVISTA (anti PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastion or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration.

OSPREY (Alcon)

A 1 year Phase 2 study that will determine the safety, tolerability and efficacy of ESBA 1008 vs aflibercept (Eylea) in Wet AMD.

OWL (Alcon)

A 2 month Phase 2 study to evaluate the effect of ESBA 1008 applied by Microvolume Injection or Infusion in Wet AMD.

PAVE (Santen)

A 3 month, phase 1, open-label, dose-escalating, sequential-cohort study assessing the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal injection of DE-122 injectable solution for the treatment of refractory exudative age-related macular degeneration.

REACH Stage 2 (Allergan)

Phase 2 study of the safety and efficacy of AGN-150998 versus ranibizumab (Lucentis) in treatment-naive patients with advanced AMD.

REACH Stage 3 (Allergan)

A 6 month Phase 2 study of the safety and efficacy of AGN-150998 vs ranibizumab (Lucentis) in treatment-naive patients with Wet AMD.

RESCUE (NCRVA & Genentech)

A 1 year Study evaluating ranibizumab (Lucentis) in Wet AMD patients previously treated with bevacizumab (Avastin) AND aflibercept (Eylea).

SAILOR (Genentech)

A comparative study evaluating the different doses of ranibizumab (Lucentis).

SEE (Alcon)

Phase 2 study of the safety, tolerability and efficacy of ESBA 1008 versus ranibizumab (Lucentis) in advanced AMD.

TAP (Novartis)

Phase 3 study of the efficacy and safety of Verteporfin with Photodynamic Therapy for the treatment of Wet AMD.

VIEW (Regeneron)

Phase 3 Study of the efficacy, tolerability and safety of repeated doses of aflibercept (Eylea).

VIEW EXTENSION (Regeneron)

Follow Up study for the patients treated with aflibercept (Eylea) for Wet AMD in the VIEW study.